IP Library Granted Patent US 11,627,912
Granted Patent B2
US 11,627,912 · App. 17/806,681 · Granted Apr 18, 2023

Managing fluid levels in a patient and associated devices, systems, and methods

Inventors: Howard R. Levin (Teaneck, NJ); Jim Dillon (Milford, MA); Andrew Halpert (Brookline, MA); Jeffrey Testani (New Haven, CT)
Assignee: Reprieve Cardiovascular, Inc.
A61B5/4839A61B5/208A61M5/142A61M2005/14208A61M2202/0496A61M2205/3327A61M2205/3396A61M2205/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,627,912
App. No.
17/806,681
Granted
Apr 18, 2023
Kind
B2
Abstract

Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.

Claims (34)

1. A fluid therapy system, comprising:

a urine measurement device configured to measure urine output from a patient;

a pump configured to provide a diuretic to the patient;

one or more processors; and

tangible, non-transitory computer-readable media having instructions that, when executed by the one or more processors, cause the fluid therapy system to perform operations comprising—

obtaining a urine output rate from the urine measurement device;

causing the diuretic to be provided, via the pump, to the patient at an initial dosage rate;

increasing the dosage rate of the diuretic from the initial dosage rate to one or more additional dosage rates higher than the initial dosage rate;

after increasing the dosage rate, receiving an indication that (i) the urine output rate is above a predetermined threshold and/or (ii) a predetermined time period since causing the diuretic to be provided has elapsed; and

after receiving the indication, reducing the dosage rate of the diuretic to a reduced dosage rate that considers multiplying a value of a total amount of the diuretic delivered by a nonzero percentage.

2. The fluid therapy system of claim 1 , wherein the nonzero percentage is within a range of 10-30%.

3. The fluid therapy system of claim 1 , wherein receiving the indication comprises receiving the indication that the urine output rate is above the predetermined threshold, and wherein the predetermined threshold is at least 300 milliliters/hour.

4. The fluid therapy system of claim 1 , further comprising, after reducing the dosage rate of the diuretic, adjusting the dosage rate based at least in part on the urine output rate increasing at a rate above a predetermined rate of increase.

5. The fluid therapy system of claim 1 , wherein automatically increasing the dosage rate of the diuretic comprises automatically increasing the dosage rate over a period of time of no more than 120 minutes.

6. The fluid therapy system of claim 1 , wherein, in operation, increasing the dosage rate occurs as the urine output rate increases.

7. The fluid therapy system of claim 1 , wherein the pump is a first pump, the fluid therapy system further comprising a second pump configured to be operably coupled to a hydration fluid and provide the hydration fluid to the patient, the operations further comprising causing the hydration fluid to be provided, via the second pump, to the patient at a hydration rate no more than the urine output rate.

8. The fluid therapy system of claim 1 , wherein the reduced dosage rate considers multiplying the value of the total amount of diuretic delivered when the indication is received.

9. A fluid therapy system, comprising:

a urine measurement device configured to measure urine output from a patient;

a pump configured to provide a diuretic to the patient;

one or more processors; and

tangible, non-transitory computer-readable media having instructions that, when executed by the one or more processors, cause the fluid therapy system to perform operations comprising—

obtaining a urine output rate from the urine measurement device;

causing the diuretic to be provided, via the pump, to the patient at a dosage rate;

after causing the diuretic to be provided, receiving an indication that (i) the urine output rate is above a predetermined threshold and/or (ii) a predetermined time period since causing the diuretic to be provided has elapsed; and

after receiving the indication, reducing the dosage rate of the diuretic, wherein the reduced dosage rate is obtained via an algorithm utilizing a nonzero percentage of a total amount of the diuretic delivered.

10. A fluid therapy system, comprising:

one or more processors; and

tangible, non-transitory computer-readable media having instructions that, when executed by the one or more processors, cause the fluid therapy system to perform operations comprising—

obtaining, from a urine measurement device, a urine output rate;

causing, by a pump, the diuretic to be provided at an initial dosage rate;

increasing the dosage rate of the diuretic from the initial dosage rate to one or more additional dosage rates higher than the initial dosage rate;

after increasing the dosage rate, receiving an indication that (i) the urine output rate is above a predetermined threshold and/or (ii) a predetermined time period since causing the diuretic to be provided has elapsed; and

after receiving the indication, reducing the dosage rate of the diuretic to a reduced dosage rate that considers multiplying a value of a total amount of the diuretic delivered by a nonzero percentage.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2022
From: LEVIN, HOWARD R.; DILLON, JIM; HALPERT, ANDREW; TESTANI, JEFFREY
To: REPRIEVE CARDIOVASCULAR, INC.
Reel/Frame 060686/0899 →
Continuity (3)
Continuation 17112925 · Dec 4, 2020
Provisional Application 62945058 · Dec 6, 2019
Related Publication 20220313158A1 · Oct 6, 2022